Eleven year-old mountaineer, Tyler Armstrong, first fell in love with conquering the outdoors when he was 7 years old. Today, he is determined to climb for a cause, on behalf of those who cannot. Tyler plans to be the youngest climber to take on Mt. Everest to help raise funds for…
News
A study recently published in the journal Biochimica et Biophysica Acta (BBA) revealed new insights into the roles played by a specific metalloprotease in a mouse model of Duchenne muscular dystrophy (DMD). The study was led by researchers at Shinshu University School of Medicine and…
Researchers at Peking University in China recently revealed new insights on the involvement of mitochondria in muscle development and muscular dystrophy in animal models. The study was recently published in the journal PLoS One and is entitled “Remodeling of Mitochondrial Flashes in Muscular Development…
A study recently published in the Journal of Translational Medicine reviewed the link between taurine and skeletal muscle disorders including muscular dystrophy. The study entitled “Taurine: the appeal of a safe amino acid for skeletal muscle disorders” was conducted by researchers at Università…
A new study recently published in the journal ACS Nano revealed a new technique to trigger muscle cell differentiation from adult stem cells using a genetic approach. The study is entitled “Inducing Stem Cell Myogenesis Using NanoScript” and was conducted by researchers at…
In a recent study published in the Journal of Pediatric Ophthalmology and Strabism, a team of researchers from Turkey found that ophthalmological problems are commonly seen in children with muscular dystrophies. Muscular dystrophy includes a group of diseases that cause progressive weakness and loss of muscle mass,…
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization on the front line against Duchenne muscular dystrophy (Duchenne), has recently announced it awarded Talem Technologies a $70,000 grant to support a pilot study concerning their X-Ar exoskeletal arm technology. This follows PPMD’s launch of their Robotics Initiative that serves to explore devices that have the potential to…
Santhera Pharmaceuticals, a Swiss pharmaceutical company specialized in developing and commercializing breakthrough treatments for orphan mitochondrial and neuromuscular diseases, announced that it has dosed the first patient in its CALLISTO Phase I trial that aims to evaluate the safety and tolerability profile of orally-stable omigapil for Congenital Muscular Dystrophy (CMD). All necessary participants have…
To help alleviate the long-term adverse effects of glucocorticoids in patients with Duchenne muscular dystrophy (DMD), a research team at Sapienza University of Rome is investigating a new form of anti-inflammatory medication that acts on inflammatory pathways in the disease. By targeting a specific mediator of inflammation in DMD, the…
Researchers at the Second University of Naples in Italy recently described the clinical characteristics of patients with a specific deletion in the dystrophin gene. The study was published in the journal Acta Myologica and is entitled “Clinical features of patients with dystrophinopathy sharing…
Recent Posts
- I’m grateful for meaningful conversations with my adult children
- Early trial data support RNA therapies for two muscular dystrophy types
- Figuring out where to buy a lift chair for my FSHD symptoms was no small task
- Sarepta plans to seek full FDA approval of 2 Duchenne treatments
- When it comes to rare disease advocacy, just keep showing up